Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Myeloperoxidase Is Not Useful for Detecting Stress Inducible Myocardial Ischemia but May Be Indicative of the Severity of Coronary Artery Disease

  • Schuhmann, Christoph G. (Department of Cardiology, Medizinische Klinik I) ;
  • Hacker, Marcus (Department of Nuclear Medicine, University Hospital of the Ludwig Maximilian University of Munich) ;
  • Jung, Philip (Department of Cardiology, Medizinische Klinik I) ;
  • Krotz, Florian (Department of Cardiology, Medizinische Klinik I) ;
  • Sohn, Hae-Young (Department of Cardiology, Medizinische Klinik I)
  • Received : 2013.06.20
  • Accepted : 2013.11.11
  • Published : 2014.01.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Elevated levels of myeloperoxidase (MPO) have been found in patients in different stages of coronary artery disease (CAD). The aim of this study was to assess whether the MPO liberation is increased by stress inducible myocardial ischemia and could be used to improve the diagnostic accuracy of non-invasive evaluation for myocardial ischemia. Subjects and Methods: Seventy-six patients with suspected myocardial ischemia who underwent stress myocardial perfusion scintigraphy (MPS) were enrolled. 59 patients with an acute coronary syndrome (ACS) who received a percutaneous coronary intervention along with 12 healthy volunteers were also included in the study. In every subject the MPO plasma levels were assessed by enzyme linked immunosorbent assay. In patients undergoing MPS, the MPO levels were measured serially before and after the stress testing. Results: Of the 76 patients undergoing MPS, 38 were diagnosed with a stress inducible myocardial ischemia. The patients with a stress induced ischemia had significantly higher basal MPO levels than those without it ($32{\pm}3ng/mL$ vs. $24{\pm}4ng/mL$, p=0.03). However, there was no relevant change in the MPO levels after the stress test compared to the baseline. The patients with ACS showed significantly higher MPO levels than the patients undergoing MPS ($131{\pm}14ng/mL$ vs. $28{\pm}2ng/mL$, p<0.01) and the healthy subjects ($131{\pm}14ng/mL$ vs. $26{\pm}2ng/mL$, p<0.01). Conclusion: Since the MPO plasma levels did not increase after the stress MPS, MPO appears not to be a useful biomarker for detecting a stress inducible myocardial ischemia. Yet, the MPO levels correlate with the different stages of CAD and may hold significance as an indicator for its clinical severity.

Keywords

Acknowledgement

Supported by : University of Munich

References

  1. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77: 598-625. https://doi.org/10.1189/jlb.1204697
  2. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003;14:353-9. https://doi.org/10.1097/00041433-200308000-00003
  3. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Schomig A, Kastrati A. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 2008;38:90-6. https://doi.org/10.1111/j.1365-2362.2007.01908.x
  4. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42. https://doi.org/10.1001/jama.286.17.2136
  5. Eggers KM, Dellborg M, Johnston N, et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem 2010;43:240-5. https://doi.org/10.1016/j.clinbiochem.2009.09.026
  6. Sawicki M, Sypniewska G, Kozinski M, et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. Eur J Clin Invest 2011;41:667-71. https://doi.org/10.1111/j.1365-2362.2010.02457.x
  7. Rebeiz AG, Tamim HM, Sleiman RM, et al. Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. Coron Artery Dis 2011;22:553-8. https://doi.org/10.1097/MCA.0b013e32834c5e98
  8. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. https://doi.org/10.1056/NEJMoa035003
  9. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5. https://doi.org/10.1161/01.CIR.0000090690.67322.51
  10. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65. https://doi.org/10.1016/j.jacc.2007.03.033
  11. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol 2007;49:1993-2000. https://doi.org/10.1016/j.jacc.2007.02.040
  12. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidasemediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-14. https://doi.org/10.1161/01.ATV.0000131784.50633.4f
  13. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-44. https://doi.org/10.1172/JCI117342
  14. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347:5-12. https://doi.org/10.1056/NEJMoa012295
  15. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894-900. https://doi.org/10.1161/01.CIR.0000042674.89762.20
  16. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999;43:860-78. https://doi.org/10.1016/S0008-6363(99)00187-X
  17. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-85. https://doi.org/10.1161/01.CIR.91.6.1872
  18. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Am Coll Cardiol 2003;42:1318-33. https://doi.org/10.1016/j.jacc.2003.08.011
  19. Slomka PJ, Hurwitz GA, Stephenson J, Cradduck T. Automated alignment and sizing of myocardial stress and rest scans to three-dimensional normal templates using an image registration algorithm. J Nucl Med 1995;36:1115-22.
  20. Wiersma JJ, Verberne HJ, Meuwese MC, et al. Myeloperoxidase is not associated with scintigraphic myocardial perfusion abnormalities in type 2 diabetic patients with mild stable anginal complaints. Clin Chim Acta 2011;412:86-90. https://doi.org/10.1016/j.cca.2010.09.019
  21. Biasucci LM, D'Onofrio G, Liuzzo G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 1996;27:611-6. https://doi.org/10.1016/0735-1097(95)00524-2
  22. Yunoki K, Naruko T, Komatsu R, et al. Relation of elevated levels of plasma myeloperoxidase to impaired myocardial microcirculation after reperfusion in patients with acute myocardial infarction. Am J Cardiol 2010;105:922-9. https://doi.org/10.1016/j.amjcard.2009.11.013
  23. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91. https://doi.org/10.1016/S0002-9440(10)64036-9
  24. Aminian A, Boudjeltia KZ, Babar S, et al. Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. Eur J Intern Med 2009;20:527-32. https://doi.org/10.1016/j.ejim.2009.05.008
  25. Marshall CJ, Nallaratnam M, Mocatta T, et al. Factors influencing local and systemic levels of plasma myeloperoxidase in ST-segment elevation acute myocardial infarction. Am J Cardiol 2010;106:316-22. https://doi.org/10.1016/j.amjcard.2010.03.028
  26. Rudolph V, Steven D, Gehling UM, et al. Coronary plaque injury triggers neutrophil activation in patients with coronary artery disease. Free Radic Biol Med 2007;42:460-5. https://doi.org/10.1016/j.freeradbiomed.2006.11.004
  27. Naruko T, Furukawa A, Yunoki K, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically- detected complex lesion morphology in unstable angina. Heart 2010;96:1716-22. https://doi.org/10.1136/hrt.2009.187609
  28. Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 2010;122:2505-13. https://doi.org/10.1161/CIRCULATIONAHA.110.955302

Cited by

  1. Complete mitochondrial genome sequence and mutations of the myocardial ischemia model inbred Sprague-Dawley strain vol.27, pp.6, 2014, https://doi.org/10.3109/19401736.2014.1003869
  2. Prognostic value of myeloperoxidase in patients with peripheral artery disease vol.29, pp.3, 2021, https://doi.org/10.1177/1708538120957491